Buy or sell Galera Therapeutics stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Galera Therapeutics Stock
Therapeutic agents for preventing damage due to radiation treatment of cancer
About Galera Therapeutics Stock
Galera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on discovering and developing novel therapeutics targeting oxygen metabolic pathways with the potential to transform how radiation therapy is used in patients with cancer. Galera’s lead product candidate is GC4419, a highly selective and potent small molecule superoxide dismutase enzyme mimetic that rapidly converts superoxide to hydrogen peroxide and oxygen. GC4419 achieved positive results in a Phase 2b clinical trial, which demonstrated its ability to reduce the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer, its lead indication. The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to GC4419.
President, Chief Executive Officer & Board of Directors
Co-Founder & Chief Scientific Officer
Dennis P. Riley
Chief Medical Officer
Jon T. Holmlund
Executive Chair, Board of Directors
Robert Alan Beardsley
Founder, Executive Chair, Board of Directors
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase